ICD-11 code 2C76.0 refers to endometrial endometrioid adenocarcinoma, a specific type of cancer that originates in the inner lining of the uterus, known as the endometrium. This subtype of endometrial cancer is characterized by the presence of glandular structures resembling normal endometrial tissue, hence the term “endometrioid adenocarcinoma.”
Endometrioid adenocarcinoma is the most common type of endometrial cancer, accounting for approximately 80% of cases. It typically affects postmenopausal women, although it can also occur in younger women. Risk factors for developing endometrial endometrioid adenocarcinoma include obesity, hormonal imbalances, and a history of certain medical conditions like diabetes and polycystic ovary syndrome.
Symptoms of endometrial endometrioid adenocarcinoma may include abnormal vaginal bleeding, pelvic pain, and pain during intercourse. Diagnosis is often made through a combination of imaging studies, such as ultrasound and MRI, as well as a biopsy of the endometrial tissue. Treatment options for this type of cancer may include surgery, radiation therapy, chemotherapy, and hormone therapy, depending on the stage and characteristics of the tumor.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The SNOMED CT code equivalent to ICD-11 code 2C76.0 (Endometrial endometrioid adenocarcinoma) is 385738002. This code is used to identify a specific type of endometrial cancer characterized by glandular structures. SNOMED CT, or Systematized Nomenclature of Medicine Clinical Terms, is a standardized medical terminology used by healthcare professionals to accurately document and communicate clinical information.
Having a specific code such as 385738002 helps ensure accuracy and consistency in coding and documentation across healthcare settings. It allows for easier information exchange, research, and analysis related to endometrial endometrioid adenocarcinoma. Healthcare organizations and providers can use this code to accurately classify and track cases of this specific type of cancer for better care coordination and treatment outcomes.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 2C76.0 (Endometrial endometrioid adenocarcinoma) may vary depending on the stage of the cancer. In the early stages, patients may experience abnormal vaginal bleeding, such as bleeding in between periods or after menopause. This can manifest as heavier periods or bleeding after intercourse.
As the cancer progresses, symptoms may become more severe. Patients may experience pelvic pain or pressure, as well as pain during sexual intercourse. Some patients may also experience pain while urinating or have difficulty emptying their bladder completely.
In advanced stages of 2C76.0 (Endometrial endometrioid adenocarcinoma), symptoms may be more pronounced. Patients may experience unintended weight loss, fatigue, and a general feeling of malaise. Some may also develop swelling in the abdomen or legs due to fluid buildup. It is important for individuals experiencing these symptoms to seek medical attention promptly for proper diagnosis and treatment.
🩺 Diagnosis
Diagnosis of 2C76.0 (Endometrial endometrioid adenocarcinoma) typically begins with a thorough medical history and physical examination by a healthcare provider. Symptoms such as abnormal vaginal bleeding, pelvic pain, or unexplained weight loss may prompt further evaluation. Diagnostic tests may include imaging studies such as ultrasound, MRI, or CT scans to visualize the uterus and surrounding structures for signs of tumor growth.
A key diagnostic tool for confirming 2C76.0 is a biopsy of the endometrial tissue. This involves collecting a small sample of tissue from the lining of the uterus and examining it under a microscope for the presence of cancer cells. Endometrial cancer is categorized into different subtypes based on the histologic appearance of the cells, with endometrioid adenocarcinoma being one of the most common types. The biopsy results help guide treatment decisions and prognosis.
In some cases, additional tests such as a dilation and curettage (D&C) procedure may be recommended to further evaluate the extent of the cancer within the uterus. This involves scraping or suctioning out tissue from the uterine lining for examination. Blood tests to assess hormone levels and tumor markers may also be performed to aid in the diagnosis and monitoring of 2C76.0. A multidisciplinary approach involving gynecologists, pathologists, radiologists, and oncologists is often necessary for accurate diagnosis and appropriate treatment planning.
💊 Treatment & Recovery
Treatment options for 2C76.0 (Endometrial endometrioid adenocarcinoma) will depend on the stage and extent of the cancer. Surgery is the primary treatment for this type of cancer and may involve a hysterectomy to remove the uterus, fallopian tubes, and ovaries. In some cases, lymph nodes and other nearby tissues may also be removed to prevent the spread of cancer cells.
In addition to surgery, radiation therapy may be used to target and destroy remaining cancer cells. This may be done externally using a machine that directs radiation to the affected area, or internally with radioactive substances placed near the cancer. Chemotherapy may also be recommended to kill cancer cells that have spread beyond the uterus. This can be given orally or intravenously and may be used in combination with radiation therapy.
Hormone therapy is another possible treatment option for endometrial cancer. This involves medications that block the effects of estrogen, which can fuel the growth of cancer cells. Targeted therapy drugs may also be used to specifically target cancer cells and inhibit their growth. It is important for patients with 2C76.0 to discuss all treatment options with their healthcare team to determine the best course of action for their specific case.
🌎 Prevalence & Risk
In the United States, endometrial endometrioid adenocarcinoma is the most common type of endometrial cancer, accounting for approximately 80% of cases. It is more prevalent in women over the age of 50 and is associated with obesity, hormonal imbalances, and a family history of the disease. The prevalence of 2C76.0 in the United States is estimated to be around 54,000 new cases diagnosed each year.
In Europe, the prevalence of endometrial endometrioid adenocarcinoma varies by country, with higher rates reported in Western European countries compared to Eastern European nations. The incidence of 2C76.0 is increasing in Europe due to factors such as aging populations, obesity rates, and changes in reproductive patterns. It is estimated that there are around 68,000 new cases of endometrial endometrioid adenocarcinoma diagnosed in Europe annually.
In Asia, the prevalence of endometrial endometrioid adenocarcinoma is lower compared to Western countries, likely due to differences in lifestyle factors, genetics, and access to healthcare. However, the incidence of 2C76.0 is increasing in countries such as Japan, South Korea, and China as a result of changing dietary habits, declining fertility rates, and an aging population. It is estimated that there are approximately 26,000 new cases of endometrial endometrioid adenocarcinoma diagnosed in Asia each year.
In Africa, the prevalence of endometrial endometrioid adenocarcinoma is relatively low compared to other regions of the world, likely due to factors such as limited access to healthcare, lower rates of obesity, and differences in reproductive patterns. However, the incidence of 2C76.0 is increasing in countries with higher socioeconomic development, such as South Africa and Nigeria. It is estimated that there are around 12,000 new cases of endometrial endometrioid adenocarcinoma diagnosed in Africa annually.
😷 Prevention
Prevention of 2C76.0 (Endometrial endometrioid adenocarcinoma) involves several important steps to reduce the risk of developing this specific type of cancer. One of the key preventive measures is maintaining a healthy lifestyle, which includes engaging in regular physical activity and maintaining a healthy weight. Obesity and lack of physical activity have been linked to an increased risk of developing endometrial cancer, so making lifestyle changes to improve overall health can help reduce the risk of developing endometrial endometrioid adenocarcinoma.
Another important aspect of prevention is managing hormone levels, particularly estrogen. High levels of estrogen in the body have been associated with an increased risk of endometrial cancer, so taking steps to regulate estrogen levels can help reduce the risk of developing 2C76.0. This can include talking to a healthcare provider about hormone replacement therapy (HRT) and other medications that can help regulate estrogen levels in the body.
Regular screening and early detection are also crucial in preventing endometrial endometrioid adenocarcinoma. Women should be aware of the signs and symptoms of endometrial cancer, such as abnormal vaginal bleeding or pelvic pain, and should seek medical attention if they experience any concerning symptoms. Additionally, women at higher risk for endometrial cancer, such as those with a family history of the disease or certain genetic mutations, should talk to their healthcare provider about screening options and starting screenings at an earlier age. By staying informed about the disease and being proactive about screening, individuals can increase their chances of detecting and treating endometrial endometrioid adenocarcinoma at an early stage, when it is most treatable.
🦠 Similar Diseases
One disease that is similar to 2C76.0 (Endometrial endometrioid adenocarcinoma) is 2C76.2 (Endometrial serous adenocarcinoma). This type of endometrial cancer is less common than endometrioid adenocarcinoma but tends to have a poorer prognosis. It is characterized by the presence of papillary structures and psammoma bodies, which are not typically seen in endometrioid adenocarcinoma.
Another disease related to 2C76.0 is 2C77.0 (Endometrial clear cell adenocarcinoma). Clear cell carcinoma accounts for only a small percentage of endometrial cancers but is often more aggressive than endometrioid adenocarcinoma. It is characterized by clear or pale cytoplasm and glycogen-rich cells, which can be distinguished from the typical features of endometrioid adenocarcinoma.
Furthermore, 2C74.0 (Endometrial mucinous adenocarcinoma) is another disease that is similar to 2C76.0. Mucinous adenocarcinoma is a rare subtype of endometrial cancer that is characterized by the presence of abundant intracellular and extracellular mucin. This type of cancer tends to behave more aggressively than endometrioid adenocarcinoma and may have a poorer prognosis.